Clinical research has added AI tools for a decade without fundamentally changing how trials run. Sites still select investigators by committee, coordinators still screen patients manually, and writers still draft protocols from scratch. The result: inter-trial delays fell from 32 months in 2022 to 17 months in 2024, then climbed again in 2025. Only 11% of sponsors and CROs have fully implemented AI for trial activities, and 66% report low confidence in underlying data quality.
AI-native operations means something different. Instead of dropping AI into existing workflows, it rebuilds workflows around AI execution with human oversight. Protocol development shifts from months of authoring to design-risk detection before finalization. Site selection moves from relationship-driven shortlists to continuous, signal-based profiling. Patient matching connects eligibility criteria directly to EHR data through FHIR APIs, replacing episodic chart review. Early adopters report 63% time savings in regulatory document prep and 65% enrollment rate improvements. The barriers are structural: data governance gaps, IP concerns, and contract standardization failures that point solutions can't fix. For sites, this means fewer redundant tools and faster activation if sponsors commit to the rebuild.